Physician profile
William A Rauh
NPI 1811914443
$4,514.15
in general payments reported to CMS, 2019-2025
26 companies · $67.43 in 2025
The $67.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,150 · 2021: $1,834 · 2024: $31.87 · 2025: $67.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,334.63 | 2019-2021 | |
| Novo Nordisk INC | $602.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $539.92 | 2019-2024 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.53 | 2019-2021 | |
| Amarin Pharma, INC. | $255.11 | 2019-2021 | |
| Lilly USA, LLC | $236.65 | 2019-2021 | |
| Abbvie INC. | $229.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $106.22 | 2020-2021 | |
| Pfizer INC. | $96.17 | 2019-2021 | |
| Amgen INC. | $84.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $74.53 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $70.89 | 2019-2021 | |
| Astellas Pharma US INC | $69.82 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $60.06 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $55.93 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.17 | 2021 | |
| Sanofi Pasteur INC. | $44.44 | 2019-2020 | |
| Dexcom, INC. | $41.45 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $20.89 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $19.39 | 2020 | |
| Ibsa Pharma INC. | $19.38 | 2021 | |
| Rgh Enterprises LLC | $19.27 | 2025 | |
| Genentech USA, INC. | $18.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2021 | |
| Mylan Specialty L.P. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rauh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.